MedTrace Logo

Ozurdex Implant for Macular Edema After Treatment Failure With Anti-VEGF

NCT01946399 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2017-12-02

No results posted yet for this study

Summary

To determine if Ozurdex implant can offer an effective treatment for macular edema associated with retinal vein occlusion when treatment with intravitreal Avastin, Lucentis, or Eylea have not demonstrated a significant response.

Conditions

  • Retinal Vein Occlusion (RVO)
  • Macular Edema

Interventions

DRUG

Ozurdex implant

Intravitreal injection of Dexamethasone implant

Sponsors & Collaborators

  • Retina-Vitreous Associates Medical Group

    collaborator OTHER

  • West Coast Retina Medical Group, Inc.

    collaborator OTHER

  • Retina Research Institute, LLC

    lead OTHER

Principal Investigators

  • Gaurav K Shah, MD · Retina Research Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2016-09-01
Completion
2017-09-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01946399 on ClinicalTrials.gov